Publication:
Oncogenic Rag GTPase signaling enhances B cell activation and drives follicular lymphoma sensitive to pharmacological inhibition of mTOR.

Research Projects

Organizational Units

Journal Issue

Abstract

The humoral immune response demands that B cells undergo a sudden anabolic shift and high cellular nutrient levels which are required to sustain the subsequent proliferative burst. Follicular lymphoma (FL) originates from B cells that have participated in the humoral response, and 15% of FL samples harbor point, activating mutations in , an essential activator of mTORC1 downstream of the sensing of cellular nutrients. The impact of recurrent mutations in B cell function and lymphoma is unexplored. mutations, targeted to the endogenous locus in mice, confer a partial insensitivity to nutrient deprivation, but strongly exacerbate B cell responses and accelerate lymphomagenesis, while creating a selective vulnerability to pharmacological inhibition of mTORC1. This moderate increase in nutrient signaling synergizes with paracrine cues from the supportive T cell microenvironment that activates B cells via the PI3K-Akt-mTORC1 axis. Hence, mutations sustain induced germinal centers and murine and human FL in the presence of decreased T cell help. Our results support a model in which activating mutations in the nutrient signaling pathway foster lymphomagenesis by corrupting a nutrient-dependent control over paracrine signals from the T cell microenvironment.

Description

We are indebted to D. M. Sabatini (R01 CA129105, R01 CA103866 and R37 AI047389) and thank R. Jaenisch, S. Markoulaki and the Whitehead Institute for Biomedical Research CRISPR facility for zygote injections. We thank A. Clear and K. Korfi for generating TMAs from lymphoma patients, and P. A. Katajisto for critical reading of the manuscript. We also thank CNIO Flow Cytometry, Histopathology, Animal Facility and Genomics Core Units for excellent technical support. Research was supported by the RETOS projects Programme of Spanish Ministry of Science, Innovation and Universities, Spanish State Research Agency, cofunded by the European Regional Development Fund (grant SAF2015-67538-R), EU-H2020 Programme (ERC-2014-STG-638891), Excellence Network Grant from MICIU/AEI (SAF2016-81975-REDT), a Ramon y Cajal Award from MICIU/AEI (RYC-2013-13546), Spanish Association Against Cancer Research Scientific Foundation Laboratory Grant, Beca de Investigacion en Oncologia Olivia Roddom, FERO Grant for Research in Oncology; Miguel Servet Fellowship and Grant Award (MS16/00112 and CP16/00112) and Project PI18/00816 within the Health Strategic Action from the ISCIII (to A.O.-M.), both cofunded by the European Regional Development Fund, Marcos Fernandez Fellowship from the Spanish Leukaemia and Lymphoma Foundation/Vistare Foundation (to A.O.-M.) and L'Oreal For Women in Science Award (to A.O.-M.). J.F. is a recipient of a Cancer Research UK Programme Award (15968) and J.O. is a recipient of a Cancer Research UK Clinician Scientist Fellowship (22742). N.M.-M. is a Ramon y Cajal Awardee MICIU/AEI (RYC-2016-20173). N.D.-S., C.C.A., A.B.P.-G. and K.T. are recipients of Ayudas de contratos predoctorales para la formacion de doctores from MICIU/AEI (BES-2016-077410, BES-2015-073776, BES-2017-081381, BES-2016-078082).

MeSH Terms

DeCS Terms

Bibliographic citation

Nat Metab . 2019 Aug;1(8):775-789.

Related dataset

Related publication

Document type